Surgical Science Sweden ABFRA:4P41 +5.67%84 Net Margin % is 7.91% as of Mar. 2026, which is 42% below its 10-year median of 13.65. GuruFocus rates FRA:4P41 with a GF Score™ of 84/100 and a GF Value™ of €13.83 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 62.28% on this metric.
The historical rank and industry rank for Surgical Science Sweden AB's Net Margin % or its related term are showing as below:
FRA:4P41'
s Net Margin % Range Over the Past 10 Years
Min: -6.88 Med: 13.65 Max: 26.5
Current: 5.34
FRA:4P41's Net Margin % is ranked better than 62.28% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs FRA:4P41: 5.34
Surgical Science Sweden AB (FRA:4P41) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Surgical Science Sweden AB Net Margin % Related Terms
Surgical Science Sweden AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4P41 vs VEEV, BTSG, TEM: Net Margin % Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (FRA:4P41) has a Net Margin % of 7.91% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Surgical Science Sweden AB and its competitors. This is 42% below median its historical median of 13.65. According to the industry distribution chart, Surgical Science Sweden AB ranks #252 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 37.7%.
Is Surgical Science Sweden AB's Net Margin % too high?
Surgical Science Sweden AB's current Net Margin % of 7.91% is 42% below median its 10-year median of 13.65. The Healthcare Providers & Services industry median Net Margin % is 2.89. Surgical Science Sweden AB's value of 7.91% is 174.2% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #252 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #252 out of 668 companies for Net Margin %. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Net Margin % is 2.89. Surgical Science Sweden AB's value of 7.91% is 174.2% above this benchmark. While the company's 10-year median is 13.65 vs. the industry median of 2.89, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Net Margin % of 7.91% is 174.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Net Margin % is 7.91%, which is 42% below median its own 10-year median of 13.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (FRA:4P41) is currently considered Significantly Undervalued. The stock's GF Value™ is €13.83, compared to a current price of €2.87 — trading 79.2% below its estimated fair value. The current Net Margin % is 7.91%, which is 42% below median its 10-year median of 13.65 and 174.2% above the Healthcare Providers & Services industry median of 2.89. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Surgical Science Sweden AB (FRA:4P41), the current Net Margin % is 7.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (FRA:4P41) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of €2.87 is trading 79.2% below its estimated GF Value™ of €13.83.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for FRA:4P41:
Net Margin %: 7.91% (42% below median its 10-year median of 13.65)
GF Value™: €13.83 vs. price of €2.87 (79.2% below fair value)
Industry Position: 174.2% above the Healthcare Providers & Services median (#252 of 668)
No single metric tells the full story. See the FRA:4P41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for FRA:4P41
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4P41 has been successfully added to your 
